Bertram Pitt

71.6k total citations · 22 hit papers
578 papers, 45.8k citations indexed

About

Bertram Pitt is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Bertram Pitt has authored 578 papers receiving a total of 45.8k indexed citations (citations by other indexed papers that have themselves been cited), including 424 papers in Cardiology and Cardiovascular Medicine, 184 papers in Endocrinology, Diabetes and Metabolism and 125 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Bertram Pitt's work include Heart Failure Treatment and Management (211 papers), Hormonal Regulation and Hypertension (151 papers) and Cardiovascular Function and Risk Factors (125 papers). Bertram Pitt is often cited by papers focused on Heart Failure Treatment and Management (211 papers), Hormonal Regulation and Hypertension (151 papers) and Cardiovascular Function and Risk Factors (125 papers). Bertram Pitt collaborates with scholars based in United States, France and United Kingdom. Bertram Pitt's co-authors include Faı̈ez Zannad, A.J. Pérez Pérez, Robert Cody, Willem J. Remme, A Castaigne, Janet Wittes, H. William Strausś, Stefan D. Anker, George L. Bakris and Janet Wittes and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Bertram Pitt

559 papers receiving 43.2k citations

Hit Papers

The Effect of Spironolactone on Morbidity and... 1975 2026 1992 2009 1999 2000 2020 2006 2000 2.0k 4.0k 6.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
    1999 6.4k citations Bertram Pitt, Faı̈ez Zannad et al. profile →
  2. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
    2000 2.4k citations Bertram Pitt, Faı̈ez Zannad et al. profile →
  3. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
    2020 1.5k citations Rajiv Agarwal, Stefan D. Anker et al. profile →
  4. The Seattle Heart Failure Model
    2006 1.5k citations Stefan D. Anker, Inder S. Anand et al. Circulation profile →
  5. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II
    2000 1.3k citations Bertram Pitt et al. The Lancet profile →
  6. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction
    1996 950 citations Bertram Pitt et al. The Lancet profile →
  7. Angiotensin-Converting Enzyme Inhibition With Quinapril Improves Endothelial Vasomotor Dysfunction in Patients With Coronary Artery Disease
    1996 837 citations Bertram Pitt et al. Circulation profile →
  8. Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure
    2000 734 citations Faı̈ez Zannad, Bertram Pitt et al. Circulation profile →
  9. A Randomized Trial of Immediate versus Delayed Elective Angioplasty after Intravenous Tissue Plasminogen Activator in Acute Myocardial Infarction
    1987 706 citations Bertram Pitt et al. profile →
  10. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
    2021 578 citations Gerasimos Filippatos, Bertram Pitt et al. European Heart Journal profile →
  11. Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors
    2014 453 citations George L. Bakris, David A. Bushinsky et al. profile →
  12. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
    2013 447 citations Bertram Pitt, Lars Køber et al. European Heart Journal profile →
  13. Sudden death in the year following myocardial infarction
    1977 417 citations Bertram Pitt et al. profile →
  14. Noncardiac Comorbidities in Heart Failure With Reduced Versus Preserved Ejection Fraction
    2014 394 citations Robert J. Mentz, Carolyn S.P. Lam et al. profile →
  15. Thallium-201 myocardial perfusion imaging at rest and during exercise. Comparative sensitivity to electrocardiography in coronary artery disease.
    1977 390 citations Bertram Pitt et al. Circulation profile →
  16. Thallium-201 for myocardial imaging. Relation of thallium-201 to regional myocardial perfusion.
    1975 380 citations Bertram Pitt et al. Circulation profile →
  17. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction
    2015 335 citations Scott D. Solomon, Brian Claggett et al. European Heart Journal profile →
  18. Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone
    2015 329 citations Amil M. Shah, Brian Claggett et al. Circulation profile →
  19. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease
    2015 312 citations George L. Bakris, Bertram Pitt et al. profile →
  20. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
    2016 299 citations Gerasimos Filippatos, Stefan D. Anker et al. European Heart Journal profile →
  21. Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes
    2017 279 citations Allan J. Collins, Bertram Pitt et al. profile →
  22. Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis
    2024 52 citations Pardeep S. Jhund, Atefeh Talebi et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bertram Pitt United States 95 32.5k 12.0k 9.0k 8.7k 6.9k 578 45.8k
Lars Køber Denmark 110 39.2k 1.2× 10.1k 0.8× 10.5k 1.2× 5.6k 0.6× 6.3k 0.9× 1.4k 59.4k
Aldo P. Maggioni Italy 107 35.8k 1.1× 9.5k 0.8× 8.0k 0.9× 5.4k 0.6× 4.1k 0.6× 873 49.2k
Milton Packer United States 109 52.9k 1.6× 10.6k 0.9× 9.4k 1.0× 8.5k 1.0× 3.2k 0.5× 655 65.6k
Karl Swedberg Sweden 111 53.2k 1.6× 9.6k 0.8× 5.9k 0.7× 8.7k 1.0× 2.8k 0.4× 507 64.0k
Faı̈ez Zannad France 102 38.6k 1.2× 19.2k 1.6× 10.2k 1.1× 11.6k 1.3× 2.1k 0.3× 958 57.7k
Gerasimos Filippatos Greece 99 30.8k 0.9× 7.9k 0.7× 6.3k 0.7× 7.5k 0.9× 2.1k 0.3× 625 43.8k
Javed Butler United States 91 29.1k 0.9× 8.1k 0.7× 6.4k 0.7× 6.2k 0.7× 2.3k 0.3× 825 42.1k
Dirk J. van Veldhuisen Netherlands 126 43.8k 1.3× 5.6k 0.5× 7.9k 0.9× 7.7k 0.9× 3.1k 0.5× 857 60.8k
Philippe Gabríel Steg France 123 56.5k 1.7× 9.9k 0.8× 30.1k 3.3× 9.8k 1.1× 10.3k 1.5× 1.1k 77.2k
Michel E. Safar France 99 31.5k 1.0× 5.7k 0.5× 7.0k 0.8× 6.8k 0.8× 2.6k 0.4× 628 39.9k

Countries citing papers authored by Bertram Pitt

Since Specialization
Citations

This map shows the geographic impact of Bertram Pitt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bertram Pitt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bertram Pitt more than expected).

Fields of papers citing papers by Bertram Pitt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bertram Pitt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bertram Pitt. The network helps show where Bertram Pitt may publish in the future.

Co-authorship network of co-authors of Bertram Pitt

This figure shows the co-authorship network connecting the top 25 collaborators of Bertram Pitt. A scholar is included among the top collaborators of Bertram Pitt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bertram Pitt. Bertram Pitt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jhund, Pardeep S., Atefeh Talebi, Alasdair Henderson, et al.. (2024). Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis. The Lancet. 404(10458). 1119–1131. 52 indexed citations breakdown →
2.
Martens, Pieter, Stephen J. Greene, Robert J. Mentz, et al.. (2024). Impact of Baseline Kidney Dysfunction on Oral Diuretic Efficacy Following Hospitalization for Heart Failure – Insights from TRANSFORM-HF. European Journal of Heart Failure. 26(5). 1242–1250. 1 indexed citations
3.
Lima‐Posada, Ixchel, Roberto Palacios, Benjamin Bonnard, et al.. (2024). Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney Disease. Journal of the American Heart Association. 13(12). e032971–e032971. 7 indexed citations
4.
5.
Wachtell, Kristian, Richard B. Devereux, Gerard P. Aurigemma, et al.. (2023). The current best drug treatment for hypertensive heart failure with preserved ejection fraction. European Journal of Internal Medicine. 120. 3–10. 12 indexed citations
6.
Greene, Stephen J., Eric J. Velazquez, Kevin J. Anstrom, et al.. (2023). Effect of Torsemide Versus Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The TRANSFORM-HF Randomized Clinical Trial. Circulation. 148(2). 124–134. 10 indexed citations
7.
Pitt, Bertram, et al.. (2022). Repurposing low-dose naltrexone for the prevention and treatment of immunothrombosis in COVID-19. European Heart Journal - Cardiovascular Pharmacotherapy. 8(4). 402–405. 13 indexed citations
8.
Agarwal, Rajiv, Stefan D. Anker, Bertram Pitt, et al.. (2021). Association of Urine Albumin-to-Creatinine Ratio and Its Early Change with Cardiorenal Outcomes in FIDELIO-DKD: A Mediation Analysis. Journal of the American Society of Nephrology. 32(10S). B5–B5.
9.
Pitt, Bertram, João Pedro Ferreira, & Faı̈ez Zannad. (2021). Why are mineralocorticoid receptor antagonists the Cinderella in evidence-based treatment of myocardial infarction complicated with heart failure? Lessons from PARADISE-MI. European Heart Journal. 43(14). 1428–1431. 5 indexed citations
10.
Pitt, Bertram, Allan J. Collins, Nancy L. Reaven, et al.. (2014). Abstract 13320: Effect of Cardiovascular Comorbidities on the Mortality Risk Associated with Serum Potassium. Circulation. 130(suppl_2). 4 indexed citations
11.
Shah, Amil M., Sanjiv J. Shah, Inder S. Anand, et al.. (2013). Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction. Circulation Heart Failure. 7(1). 104–115. 327 indexed citations
12.
Moukarbel, George V., Zi‐Fan Yu, Kenneth Dickstein, et al.. (2013). The Impact of Kidney Function on Outcomes Following High Risk Myocardial Infarction: Findings from 27 610 Patients. European Journal of Heart Failure. 16(3). 289–299. 16 indexed citations
13.
Pitt, Bertram, Gerasimos Filippatos, Mihai Gheorghiade, et al.. (2012). Rationale and Design of ARTS: A Randomized, Double-Blind Study of BAY 94-8862 in Patients with Chronic Heart Failure and Mild or Moderate Chronic Kidney Disease. European Journal of Heart Failure. 14(6). 668–675. 78 indexed citations
14.
Preiss, David, Dirk J. van Veldhuisen, Naveed Sattar, et al.. (2012). Eplerenone and New-Onset Diabetes in Patients with Mild Heart Failure: Results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). European Journal of Heart Failure. 14(8). 909–915. 55 indexed citations
15.
Dobre, Daniela, Patrick Rossignol, Ján Murín, et al.. (2012). Statin Therapy and Clinical Outcomes in Myocardial Infarction Patients Complicated by Acute Heart Failure: Insights from the EPHESUS Trial. European Journal of Heart Failure. 15(2). 221–227. 8 indexed citations
16.
Zannad, Faı̈ez, John J.V. McMurray, Helmut Drexler, et al.. (2010). Rationale and Design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). European Journal of Heart Failure. 12(6). 617–622. 56 indexed citations
17.
Wu, Audrey H., Bertram Pitt, Stefan D. Anker, et al.. (2010). Association of Obesity and Survival in Systolic Heart Failure After Acute Myocardial Infarction: Potential Confounding by Age. European Journal of Heart Failure. 12(6). 566–573. 26 indexed citations
18.
Adamopoulos, Chris, Ali Ahmed, Renaud Fay, et al.. (2009). Timing of Eplerenone Initiation and Outcomes in Patients with Heart Failure After Acute Myocardial Infarction Complicated by Left Ventricular Systolic Dysfunction: Insights from the EPHESUS Trial. European Journal of Heart Failure. 11(11). 1099–1105. 58 indexed citations
19.
McMurray, John J.V., Bertram Pitt, Roberto Latini, et al.. (2008). Effects of the Oral Direct Renin Inhibitor Aliskiren in Patients With Symptomatic Heart Failure. Circulation Heart Failure. 1(1). 17–24. 276 indexed citations
20.
White, William B., Vladimir Hanes, Vijay S. Chauhan, & Bertram Pitt. (2006). Effects of a New Hormone Therapy, Drospirenone and 17-β-Estradiol, in Postmenopausal Women With Hypertension. Hypertension. 48(2). 246–253. 83 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lars Køber Breakdown of academic impact, for papers by Aldo P. Maggioni Breakdown of academic impact, for papers by Milton Packer Breakdown of academic impact, for papers by Karl Swedberg Breakdown of academic impact, for papers by Faı̈ez Zannad Breakdown of academic impact, for papers by Gerasimos Filippatos Breakdown of academic impact, for papers by Javed Butler Breakdown of academic impact, for papers by Dirk J. van Veldhuisen Breakdown of academic impact, for papers by Philippe Gabríel Steg Breakdown of academic impact, for papers by Michel E. Safar
Rankless by CCL
2026